[HTML] nih.gov

[HTML][HTML] Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN

TH Chu, HH Chan, HM Kuo, LF Liu, TH Hu, CK Sun… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Celecoxib, a COX-2 inhibitor and non-steroidal anti-inflammatory drug, can prevent several
types of cancer, including hepatocellular carcinoma (HCC). Here we show that celecoxib
suppressed the self-renewal and drug-pumping functions in HCC cells. Besides, celecoxib
depleted CD44+/CD133+ hepatic cancer stem cells (hCSC). Prostaglandin E2 (PGE2) and
CD133 overexpression did not reverse the celecoxib-induced depletion of hCSC. Also,
celecoxib inhibited progression of rat Novikoff hepatoma. Moreover, a 60-day celecoxib …
被引用次数：75 相关文章 所有 14 个版本
[PDF] academia.edu

[PDF][PDF] Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN

KHC Ma, KH Lai, ZH Wen13, PI Hsu, MH Tai - academia.edu
Celecoxib, a COX-2 inhibitor and non-steroidal anti-inflammatory drug, can prevent several
types of cancer, including hepatocellular carcinoma (HCC). Here we show that celecoxib
suppressed the self-renewal and drug-pumping functions in HCC cells. Besides, celecoxib
depleted CD44+/CD133+ hepatic cancer stem cells (hCSC). Prostaglandin E2 (PGE2) and
CD133 overexpression did not reverse the celecoxibinduced depletion of hCSC. Also,
celecoxib inhibited progression of rat Novikoff hepatoma. Moreover, a 60-day celecoxib …
相关文章
以上显示的是最相近的搜索结果。 查看全部搜索结果